Zoe LE van Kempen
Overview
Explore the profile of Zoe LE van Kempen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toorop A, Wessels M, Boonkamp L, Gelissen L, Hoitsma E, Zeinstra E, et al.
Mult Scler
. 2024 Nov;
30(13):1683-1688.
PMID: 39494701
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) and serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology of natalizumab wearing-off symptoms (WoSs). Objectives:...
2.
van Lierop Z, Wessels M, Lekranty W, Moraal B, Hof S, Hogenboom L, et al.
Mult Scler
. 2024 Oct;
30(13):1620-1629.
PMID: 39420574
Background And Objectives: Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions...
3.
Coerver E, Kacar S, Ciccarelli O, Sormani M, Barkhof F, Arnold D, et al.
Mult Scler
. 2024 Sep;
30(10):1296-1308.
PMID: 39245991
Background: Higher age is associated with less inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS). It is unknown whether age itself or disease duration underlies this association. Objectives: This study...
4.
Toorop A, Noteboom S, Steenwijk M, Gravendeel J, Jasperse B, Barkhof F, et al.
Mult Scler
. 2024 Jan;
30(2):266-271.
PMID: 38235514
Background: Extended interval dosing (EID) of natalizumab treatment is increasingly used in multiple sclerosis. Besides the clear anti-inflammatory effect, natalizumab is considered to have neuroprotective properties as well. Objectives: This...
5.
Toorop A, van Lierop Z, Gelissen L, Hoitsma E, Zeinstra E, van Rooij L, et al.
J Neurol Neurosurg Psychiatry
. 2023 Nov;
95(5):392-400.
PMID: 37963723
Background: Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment...
6.
van Kempen Z, van Dam K, Keijser J, Stalman E, Kummer L, Strijbis E, et al.
Mult Scler
. 2023 Nov;
30(3):443-447.
PMID: 37942812
Background: Humoral responses after SARS-CoV-2 vaccination are greatly impaired in multiple sclerosis (MS) patients on fingolimod. Effects of repeated vaccination and infections on long-term responses are unclear. Methods: Prospective study...
7.
Wessels M, van Lierop Z, Noteboom S, Strijbis E, Heijst J, van Kempen Z, et al.
Mult Scler
. 2023 Aug;
29(10):1229-1239.
PMID: 37530045
Background: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarkers that monitor neuroinflammation, neurodegeneration, treatment response, and disease progression despite treatment. Objective: To assess the value of...
8.
van Kempen Z, Mazziotti V
Mult Scler
. 2023 Jul;
29(8):901-903.
PMID: 37431629
No abstract available.
9.
Toorop A, Steenhuis M, Loeff F, Weijers S, Killestein J, Rispens T, et al.
Mult Scler
. 2022 Nov;
29(3):457-460.
PMID: 36448735
Background: Natalizumab via subcutaneous administration was recently approved for patients with multiple sclerosis. Objective: In light of personalized extended dosing, in which treatment intervals are prolonged to a concentration cut-off,...
10.
van Lierop Z, Noteboom S, Steenwijk M, van Dam M, Toorop A, van Kempen Z, et al.
Mult Scler
. 2022 Sep;
28(14):2231-2242.
PMID: 36062492
Background: Despite highly effective treatment strategies for patients with relapsing-remitting multiple sclerosis (RRMS), long-term neurodegeneration and disease progression are often considerable. Accurate blood-based biomarkers that predict long-term neurodegeneration are lacking....